SHC

SHC, approved by the Shanghai Municipal People's Government and initiated by Shanghai Industrial Group, has a total fund size of 50 billion RMB, with the first phase being 10 billion RMB. SHC will fully utilize the comprehensive advantages of developing biomedicine in Shanghai, relying on the financial and industrial resources of all partners, to build an innovative investment platform in the biomedicine sector that is "rooted in Shanghai and Hong Kong, linked with the Yangtze River Delta, and facing the world." SHC will fully seize the unique opportunities brought by "market operations + industrial empowerment + policy guidance," combining financial capital with industrial resources and integrating domestic and overseas operations, to focus investments in key areas that align with Shanghai's biomedicine industry development strategy. These include major project areas such as biologics, innovative chemical drugs, research and development outsourcing and services, medical devices and diagnostics, and innovative business models in the healthcare sector.